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Abstract
The covalent attachment of an innate immune system stimulating agent to an antigen can provide active vaccine modalities capable
of eliciting a potent immune response against the incorporated antigen. Here we describe the design, automated synthesis and
immunological evaluation of a set of four muramyl dipeptide–peptide antigen conjugates. Muramyl dipeptide (MDP) represents a
well-known ligand for the intracellular NOD2 receptor and our study shows that covalently linking an MDP-moiety to an antigenic
peptide can lead to a construct that is capable of stimulating the NOD2 receptor if the ligand is attached at the anomeric center of
the muramic acid. The constructs can be processed by dendritic cells (DCs) and the conjugation does not adversely affect the
presentation of the incorporated SIINFEKL epitope on MHC-I molecules. However, stimulation of the NOD2 receptor in DCs was
not sufficient to provide a strong immunostimulatory signal.
Introduction
In recent years the study of pattern recognition receptors
(PRRs) and associated ligands has evolved tremendously [1].
The discovery of Toll-like receptors (TLRs) [2] in the late
1990s has had a major impact on the field of immunology. This
is reflected in the exploration of conjugates consisting of a
PRR-ligand (PRR-L) covalently bound to antigenic proteins and
oligopeptides in the development of new (semi)synthetic
vaccine modalities [3-9]. For instance, the group of Boons
investigated a three-component conjugate containing a tumor-
associated glycopeptide and a T cell epitope covalently bound
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Figure 1: MDP-antigen conjugates 2–5. DEVA5K = DEVSGLEQLESIINFEKLAAAAAK.
to a TLR2 ligand [10,11]. Previously we have reported on the
design, synthesis and immunological evaluation of constructs of
TLR ligands covalently linked to a synthetic long peptide
harboring a major histocompatibility complex (MHC) class I
specific epitope [12]. Either the structurally defined TLR2-
ligand Pam3CSK4 [13,14], TLR7-ligand 7-hydroxy-8-oxoade-
nine [15] or TLR9-ligand CpG DNA [13] were covalently
bound to a model antigen, an ovalbumin derived peptide
comprising the MHC I epitope SIINFEKL, embedded in a
longer peptide motif (DEVSGLEQLESIINFEKLAAAAAK,
DEVA5K) [13,16]. We revealed that conjugates, in which
Pam3CSK4 or CpG DNA were incorporated, showed an
increased uptake of conjugated peptide. Increased DC matura-
tion and enhanced antigen presentation was achieved in com-
parison to the mixture of the single peptide and ligands [13,14].
In the late 1990s the cytosolic nucleotide-binding oligomeriza-
tion domain (NOD) receptors [17] NOD1 [18] and NOD2 [19]
were discovered to be intracellular PRRs [20,21]. NOD1 and
NOD2 recognize specific parts of peptidoglycan (PG), found in
the bacterial cell wall [22,23]. PG consists of a polysaccharide
chain of β-(1–4) linked N-acetylglucosamine (GlcNAc) and
N-acetylmuramic acid (MurNAc) of which the lactic acid is
connected to a peptide [24]. Where NOD1 recognizes
diaminopimelic acid containing peptides [25,26], the minimal
structural element of PG required for activation of the intracel-
lular protein NOD2 is N-acetylmuramyl-L-alanine-D-isogluta-
mine (MDP, Figure 1, 1) [27-30]. Based on the effectiveness of
the above mentioned TLR2/9-ligand conjugates, we hypothe-
sized that constructs consisting of a NOD2 ligand covalently
bound to the ovalbumin derived model peptide (DEVA5K)
could lead to similar enhanced immunological activity. Impor-
tant issues in the design of such conjugates are the selection of a
suitable MDP derivative and the position of the covalent
linkage between the NOD2-ligand and the peptide epitope [31-
33]. Besides, the nature of the interaction between MDP and
NOD2 receptor at the molecular level has not been established
yet. Therefore we considered different linkages between MDP
and the antigenic peptide (Figure 1) and we decided to hook up
the NOD2 ligand to either the N- or C-terminus. As a point of
attachment on the ligand we opted for a linker connected to the
anomeric center of the MDP or the carboxylic acid function of
isoglutamine as viable conjugation sites. It is known that the
size and orientation of the aglycon installed at the anomeric
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center of MDP influences its immunological activity [18,34]
and therefore we selected an 3-azidopropanol spacer as conju-
gation handle with minimal steric bulk. With respect to the
second conjugation site, i.e., the isoglutamine residue, it has
been reported that condensation of this acid with an unnatural
amine does not affect the immunological properties of MDP
[34]. A conjugate of the anticancer drug Paclitaxel with MDP
has been described using this conjugation locus, which not only
showed antitumor activity but also immunostimulatory effects
[35]. Also, the commercially available immunomodulator
Murabutide, a glutamine n-butyl ester derivative of MDP,
supports the notion that modifications on the isoglutamine are
allowed [36]. Thus, MDP-antigen conjugates 2–5 were selected
as target molecules (Figure 1). In conjugate 2 the carboxylic
acid function of the isoglutamine of the MDP is linked to the
N-terminal amine of the antigenic peptide. In conjugate 3 the
same acid function of the MDP connects to the C-terminal
lysine of the antigenic peptide. The 3-azidopropanol spacers at
the anomeric center of MurNAc in conjugate 2 and 3 remain
unmodified. In conjugates 4 and 5 on the other hand the
3-azidopropanol is functionalized with glutamic acid allowing
conjugation to the antigenic peptide at the N-terminus for
conjugate 4 and at the C-terminus for conjugate 5.
We here describe the assembly of MDP building blocks, suit-
able for automated solid phase peptide synthesis (SPPS), their
use in the assembly of the four MDP-antigen conjugates 2–5
and the immunological evaluation of the constructs.
Results and Discussion
Synthesis of the conjugates
The MDP-antigen conjugates 2–5 were prepared using an auto-
mated solid-phase peptide synthesis (SPPS) protocol. In all
these syntheses commercially available Tentagel S RAM resin
and amino acids were applied. The synthesis of the required
MDP building blocks 10 and 16 is depicted in Scheme 1. The
3-azidopropanol spacer was attached to the anomeric center of
the glucosamine moiety using oxazoline 6 [37-39]. Deacetyl-
ation and subsequent installation of the benzylidene protective
group then gave alcohol 9. Coupling of 9 with (S)-2-chloro-
propanoic acid in the presence of sodium hydride resulted in the
formation of protected MurNAc 10 in 93% yield [39,40]. Fully
protected MDP 14 was obtained by condensation of acid 10 and
dipeptide 13. To this end, Fmoc-protected tert-butyl glutamic
acid 11 was reacted with di-tert-butyl dicarbonate and trans-
formed into 12 [41]. In a one-pot procedure compound 12 was
deprotected with DBU and after quenching the reaction mix-
ture with HOBt, the free amine was condensed with Fmoc-
protected alanine to give compound 13 in 82% yield. The same
procedure was applied to condense MurNAc 10 with dipeptide
13, using the more reactive coupling reagent HATU. Despite
the low solubility of MurNAc 10 and dipeptide 13, building
block 14 was obtained in 70% yield. Isolation and purification
of key intermediate 14 was substantially facilitated by the
finding that the compound could be efficiently precipitated from
a MeOH/DCM/diethyl ether solvent mixture. The synthesis of
building block 16 started with the reduction of the azide in com-
pound 14 with PMe3 and subsequently the primary amine and
Fmoc protected glutamic acid allyl ester were condensed under
influence of HATU and DiPEA to give the orthogonally
protected compound 15 in 57% yield. To make 15 suitable for
SPPS, the allyl protective group was removed with Bu3SnH and
Pd(PPh3)4 under acidic conditions yielding compound 16 in
72% [42].
For the immunological evaluation of conjugates 2–5 relevant
reference compounds are needed, and to this end we assembled
MDP derivative 20. On paper, acidic removal of the Boc and
benzylidene protecting groups in 14 could lead to reference
compound 20 in a single step. However, treatment of 14 with a
solution of 20% TFA in DCM was accompanied by hydrolysis
of the glycosidic linkage. To suppress acid-mediated hydrolysis
a stepwise deprotection procedure was followed in which the
benzylidene group was first replaced by electron-withdrawing
acetyl groups. This protective group pattern provides higher
acid stability of the glycosidic linkage and permits removal of
the Boc group using more stringent conditions. Thus, treatment
of 14 with 60% aqueous acetic acid in the presence of two
equivalents of neopentyl glycol at 60 °C and careful monitoring
of the reaction progress led to compound 17 in 88% yield.
Acetylation of 17 then afforded compound 18. Stabilization of
the glycosidic linkage by the installment of electron-with-
drawing groups proved to be successful, and the treatment of 18
with 20% TFA in DCM resulted in compound 19 in 82% yield.
During the reaction only a minimal amount of hydrolysis was
observed. The synthesis was continued by the treatment of 19
with ammonia in MeOH and ensuing purification of the crude
product using HW40 gel filtration to result in reference com-
pound 20 in 87% yield.
With MurNAc building block 10 and 16 in hand, the solid-
phase peptide synthesis of the MDP-antigen conjugates 2–5 was
undertaken (Scheme 2). Commercially available Fmoc
protected amino acids equipped with standard acid labile
protective groups were used. The side chain of the C-terminal
lysine of the antigenic peptide was protected with the methyl
trityl (Mtt) protective group, allowing the modification of both
the N- or C-terminal end at the final stage of the synthesis. In a
standard elongation cycle using HCTU as a coupling reagent,
acetic anhydride as capping reagent and piperidine to remove
the Fmoc-group, immobilized peptide 21 was assembled using
fully automated peptide synthesis (Scheme 2). To obtain conju-
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Scheme 1: a) TMSOTf, DCM, 83%; b) cat. NaOMe, MeOH, quant.; c) CSA, PhCH(OMe)2, MeCN, DMF, 86%; d) (S)-2-chloropropionic acid, NaH,
1,4-dioxane, 93%; e) Boc2O, NH4HCO3, pyridine, 1,4-dioxane, 99%; f) 1) DBU, HOBt, DCM; 2) Fmoc-L-Ala-OH, EDC, DIPEA, DCM, 82%; g) 1) 13,
DBU, HOBt, DCM; 2) 12, HATU, DIPEA, DCM, 70%; h) 1) Me3P (solution in THF), DMF, THF, 80%; 2) Fmoc-Glu-(OH)-OAllyl, HATU, DIPEA, DMF,
57%; i) Pd(PPh3)4, Bu3SnH, AcOH, DMF, 72%; j) 60% AcOH, H2O, neopentylglycol, 88%; k) Ac2O, pyridine; l) 20% TFA, DCM, 82% (2 steps);
m) NH4OH, MeOH, 87%.
gate 2 with MDP on the N-terminus of the peptide, peptide 21
was consecutively elongated with Fmoc-D-isoglutamine, Fmoc-
L-alanine and MurNAc 10. The coupling of MurNAc 10
involved a double coupling protocol, using HATU instead of
HCTU as condensing agent. The obtained fully protected and
immobilized precursor was treated with a cocktail of 95% TFA,
2.5% TIS and 2.5% H2O to give, after precipitation in Et2O,
conjugate 2 and the hydrolyzed conjugate 22 in a 1:1 ratio.
Purification by RP-HPLC resulted in the isolation of pure
conjugate 2 (2% overall yield).
In the next target conjugate 3, MDP occupies the C-terminal
position of the antigenic peptide. To obtain 3, the N-terminus of
immobilized peptide 21 was protected with a Boc-group by
treatment of 21 with 1 M Boc2O in NMP and two equivalents of
DIPEA (Scheme 2). Next, the resin was treated with a solution
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Scheme 2: a) 20% piperidine, NMP; b) Fmoc SPPS DEVA5K; c) Fmoc-D-isoGln-OH, HCTU, DIPEA, NMP; d) Fmoc-L-Ala-OH, HCTU, DIPEA, NMP;
e) 10, HATU, DIPEA, NMP; f) 95% TFA, 2.5% H2O, 2.5% TIS; g) Boc2O, NMP, DIPEA; h) 3% TFA, DCM. i) 16, HATU, DIPEA, NMP; j) 16, DIPEA,
HCTU, DMSO, DMF.
of 3% TFA in DCM to selectively remove the Mtt protective
group from the side chain of the C-terminal lysine. The
resulting free amine was consecutively elongated with Fmoc-D-
isoglutamine, Fmoc-L-alanine and MurNAc 10 as described for
conjugate 2. Subsequently, the resin was subjected to the
cleavage cocktail (95% TFA, 2.5% TIS and 2.5% H2O) to give
conjugate 3 and the hydrolyzed conjugate 25 in a 1:1 ratio.
Purification by RP-HPLC gave pure conjugate 3 (2% overall
yield).
Conjugate 4 was obtained by the application of advanced
building block 16 (Scheme 1). En route to 4, peptide 21 was
elongated with 16 in a coupling cycle using HATU as a
coupling reagent (Scheme 2). The solid-phase synthesis scheme
was concluded with the removal of the Fmoc protective group
resulting in the partially protected immobilized precursor of 4.
Acidic cleavage of all protecting groups and release of the
target conjugate from the resin gave, after precipitation of the
crude product from Et2O at –20 °C and RP-HPLC purification,
pure conjugate 4 in 2% overall yield.
To synthesize the C-terminal functionalized conjugate 5, Tent-
agel S RAM resin was first condensed with building block 16,
which turned out to be challenging. Changing the solvent mix-
ture from pure NMP to 20% DMSO in NMP led to 26 with a
moderate coupling efficiency of 56% as judged from an Fmoc-
cleavage test of an aliquot of resin. The Fmoc protective group
in 26 was removed and the resin was elongated by automated
SPPS with the DEVA5K motif resulting in the immobilized
fully protected conjugate. The same deprotection and cleavage
conditions as described for 4 were used to isolate conjugate 5.
Treatment of the resin with the cleavage cocktail for a shorter
reaction time reduced the anomeric hydrolysis of the conjugate.
Purification by RP-HPLC gave pure conjugate 5 in 6% overall
yield.
Immunological evaluation of the MDP-antigen
conjugates
The immunostimulatory activity of conjugates 2–5 was assessed
in three different assays. In these assays, besides reference com-
pound 20, also the unconjugated peptide, DEVA5K (29), and
the Pam3Cys-antigen conjugate 30 were used as relevant
control compounds [13]. In the first assay the NOD2 stimula-
tory potential of the conjugates was assessed. In the second and
third assay the conjugates were evaluated for their potential to
induce maturation of dendritic cells (DCs) and their ability to
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Figure 2: Potency of the NOD2-L antigen conjugates 2–5 in NOD2 transfected HEK cells.
support uptake followed by antigen processing and presentation
by DCs. The MHC class I molecule Kb on DCs derived from
C57BL/6 mice is able to present the SIINFEKL epitope
(OVA257-264), which is embedded in the antigenic long
peptides. Presentation of the SIINFEKL-antigen can be
measured by adding a CD8+ T cell hybridoma (B3Z),
which is specific for the SIINFEKL epitope. This hybridoma
contains a lacZ reporter construct linked to the nuclear factor of
activated T cells (NFAT), enabling colorimetric measurement
of the level of T cell receptor mediated activation of this T cell
clone.
The NOD2 activating capacity of conjugates 2–5 was tested
using a stable NOD2 transfected human embryonic kidney
(HEK293) cell line, in which the level of interleukin 8 (IL-8)
production reflects the NOD2 stimulatory capacity of the com-
pounds (Figure 2). MDP derivative 20 showed a substantial
amount of IL-8 production, confirming that the β-azido-
propanol modification on the anomeric position is allowed
[43,44]. Of conjugates 2–5 the conjugates 2 and 3 showed
activity close to background levels. In contrast, conjugates 4
and 5 induced IL-8 production at a level comparable to MDP
derivative 20. The difference in the activity of conjugates 2 and
3 compared to 4 and 5 indicates that the attachment point of the
MDP to the antigenic peptide is important. Conjugation at the
GlcNAc anomeric center of MDP as in conjugates 4 and 5 is
more favorable than conjugation to the side chain of the L-iso-
glutamic acid residue (2, 3). The negative controls, peptide 29
and conjugate 30, showed no activity indicating that the activi-
ties of 4 and 5 are a consequence of the presence of the MDP in
these conjugates. Notably, the location of the ligand on either
the C- or N-terminus of the peptide (4 vs 5) does not seem to
affect the NOD2 stimulating activity significantly, although the
N-terminal conjugate appears slightly more active than the
C-terminal conjugated MDP.
The ability of conjugates 2–5 to induce DC maturation was
evaluated by measuring interleukin 12 (IL-12p40) production
by the cultured murine DC line, D1 [45]. IL-12 secretion by
DCs is a good indicator for the immunostimulatory potential of
a compound, because this cytokine is essential for T cell stimu-
lation and differentiation upon presentation by these antigen
presenting cells. In Figure 3 it is shown that conjugates 2–5
produce amounts of IL-12 that are close to background level. In
agreement with the results of the NOD2 transfected HEK cells
conjugates 4 and especially 5 are more active than 2 and 3 indi-
cating that the MDP ligation locus affects the activity of the
constructs. Notably, reference Pam3Cys-conjugate 30 is much
more potent than MDP-conjugates 4 and 5. A possible explan-
ation for the lack of strong maturating activity of the conju-
gates 4 and 5 is that these conjugates are not effectively inter-
nalized and therefore only a very low concentration reaches the
cytosol resulting in a poor stimulation of the NOD2 receptor
[46].
Finally, the influence of the MDP-modification on the MHC
I-mediated presentation of the antigenic peptide was investi-
gated using the SIINFEKL-specific T-cell hybridoma (B3Z)
assay. The DCs were treated with constructs 2–5 and reference
compounds 29 and 30 (Figure 4). All constructs gave rise to
antigen presentation, which indicates that the presentation is not
affected by the condensation of an MDP to either C- or
N-terminus of the antigenic peptide. Known conjugate 30
containing TLR-2 ligand Pam3CSK4 showed, as previously
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Figure 3: DC activation of the conjugates 2–5 and reference compounds 29 and 30.
Figure 4: Antigen presentation of the conjugates 2–5 and reference compounds 29 and 30.
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reported, an increased level of antigen presentation in compari-
son to peptide 29 [13].
Collectively, the data obtained from the assays described indi-
cate that the MDP-based conjugates 2–5 are poor maturating
agents for murine dendritic cells while antigen presentation
from the peptide part of the constructs is retained. Since the
NOD2 activity of constructs 4 and 5 is intact as determined by
the assay using the NOD-2 transfected cell line, the overall
failure of the described construct to mature DCs is probably not
caused by the lack of receptor binding. The NOD2 receptor is
located in the cytosol and the mechanisms underlying NOD2
ligand internalization and processing, before reaching the
receptor in the cytosol are not yet fully understood [46]. There
are indications that PG fragments are internalized via endocy-
tosis and subsequently processed and transported to the cytosol.
Because the antigen presentation assay indicates that the NOD2
modified peptides are processed correctly and presented by the
MHC class I molecules, we assume that the poor activity of the
MDP-conjugates is not (solely) due to the inability of these to
reach the cytosol of the DC. Presumably the NOD2 triggering
by MDP in the used murine DC cell line is comparatively inef-
fective as compared to the NOD2 transfected HEK cells.
Conclusion
We have described the assembly of two MDP building blocks,
suitable for automated solid-phase peptide synthesis, and their
application in the construction of a set of four MDP-peptide
conjugates. These conjugates comprised a C- or N-terminal
ligation of the MDP to the antigenic SIINFEKL peptide via
either the L-isoglutamine function or the C-1 of MDP. During
the synthesis the glycosidic bond of MDP turned out to be
sensitive to acidic deprotection conditions, resulting in partial
hydrolysis of the aglycon. Nevertheless, pure MDP derivatives
and conjugates could be isolated. The NOD2 stimulatory poten-
tial critically depended on the mode of ligation. Where the
constructs that were conjugated via the anomeric center of MDP
showed good NOD2 activation, the conjugates linked to the
antigenic peptide through the L-isoglutamine residue were
devoid of such stimulating capacity. Conjugation of the MDP-
ligands to the antigenic peptide did not hamper the antigen
presentation, although the conjugates only showed a marginal
DC maturation potential. This indicates that the conjugates can
be taken up by DCs and properly processed, but that the NOD2
ligand does not trigger the receptor effectively enough to in-
duce maturation of these murine DCs. It is known however, that
there are differences in NOD sensitivity between human and
murine DCs. To increase the potency of NOD2 ligands,
lipophilic MDP derivatives have been developed and it might
well be that these can display a more favorable uptake profile
than the relatively polar MDP-conjugates (2–5) described here.
Conjugates of these lipophilic MDPs can therefore be attractive
vaccine modalities and efforts are currently underway in our
laboratory to investigate these.
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